Saad, F.

cancer patient prostate trial prostate cancer docetaxel phase treatment study metastatic survival therapy factor chemotherapy oncol disease progression response receptor prednisone european clinicaltrials.gov identifier urology androgen group randomised effect carcinoma growth combination result agent cell carcinoma randomized hormone-refractory tax 327 study hormone-refractory prostate cancer metastase clusterin mitoxantrone nomogram protein activity level metastatic crpc phase 2 trial bladder cancer inhibitor delegate identifier clinicaltrials.gov prognostic castration sunitinib expression model placebo evidence retreatment sano fi aventis decline mcrpc sternberg mechanism radiation apoptosi bladder prognostic factors antigen benefit hormone cisplatin second-line atrasentan endpoint localised immunotherapy family oncology castration-resistant prostate cancer